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Introduction: The aim of this study was to assess the significance
of microscopic vascular invasion (MVI) in a population of resected
patients with early-stage non-small cell lung cancer (NSCLC), along
with an analysis of the effect of the combination of MVI and tumor
size for the T-size categories T1a-T2b according to the 2009 7th
edition of the tumor, node, metastasis (TNM) classification.
Methods: From January 1993 to August 2008, 746 patients with
pT1-T2N0 NSCLC received resection at our institution. MVI was
ascertained using histopathological and immunohistochemical tech-
niques.
Results: MVI was observed in 257 patients (34%). Prevalence was
higher in adenocarcinoma (ADK) than in squamous cell carcinoma
(p  0.002). A significant correlation was found between MVI and
ADK (p  0.03), increased tumor dimension (p  0.05), and the
presence of tumor-infiltrating lymphocytes (p 0.02). The presence
of MVI was associated with a reduced 5-year survival overall (p 
0.003) and in ADK (p 0.0002). In a multivariate survival analysis,
MVI was an indicator of poor survival overall (p  0.003) and in
ADK (p  0.0005). In each T category (T1a-T2b) of the 2009 TNM
staging system, survival of MVI patients was significantly lower
than the corresponding MVI patients; T1a and T1b MVI patients
had a survival similar to MVI T2 patients.
Conclusions: The finding of MVI in pT1-T2N0 NSCLC is fre-
quent. MVI correlates with adenocarcinoma histotype, increased
tumor dimensions, and tumor-infiltrating lymphocytes. The pres-
ence of MVI is an independent negative prognostic factor. In our
experience, MVI was a stronger prognostic indicator than T size
in T1a-T2b categories according to the 2009 TNM staging
system.
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Lung cancer is the leading cause of cancer-related deathsamong men and women. Despite recent improvements in
early diagnosis and treatment, the overall 5-year survival
rate is a dismal 15%.1 Even patients at stage I disease have
a 5-year survival rate ranging from 65 to 73%, well below
that of most other solid organ tumors, and about two-third
of stage I patients eventually die of distant metastases. For
this reason, many authors have looked for clinicopatho-
logic markers that can reliably be used as prognostic
indicators, as well as a guide to identify patients who are
most likely to benefit from adjunct therapies. Among
others, microscopic vascular invasion (MVI), including
intratumoral blood vessel invasion (BVI) and lymphatic
vessel invasion (LVI), has been reported to be important
prognostic factors in early stages2,3 or in all stages4,5 of
non-small cell lung cancer (NSCLC). Furthermore, tumor
size has recently been identified as a significant prognos-
ticator, and in the most recent 7th edition of the tumor,
node, metastasis (TNM) staging system of lung cancer,6
several subgroups of T categories by size at 2, 3, 5, 7, and
7 cm have been introduced, showing definite survival
stratification.
Surprisingly, despite MVI defined as BVI, LVI, or a
combination of both has been found to represent a major
determinant of poor prognosis in most surgical series since
the 1960s; it has received little interest in all the TNM
editions, and even the last 2009 7th edition indicates MVI
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among the “optional descriptors,” which deserve further in-
vestigation.
Therefore, the aim of this study was to assess, in a
surgical population of resected patients with NSCLC at stage
I–II pT1-T2N0M0, prevalence, correlation with other clini-
copathologic variables, and prognostic significance of MVI,
along with an analysis of the effect of the combination of
MVI and tumor size for the T-size categories T1a-T2b using
the 2009 7th edition of the TNM classification.
PATIENTS AND METHODS
This retrospective study included 746 patients with
pathologic T1-T2N0 NSCLC who underwent resection at the
Section of Thoracic Surgery of the University of Torino,
Italy, between January 1993 and August 2008, and who
represent the study population. In the same period, a total of
1515 patients received resection for NSCLC. In the study
population, the presence of MVI was investigated on the
surgical specimen, and the patients were divided into two
different groups, MVI and MVI. None of the patients
received induction chemotherapy or radiotherapy. Routine
preoperative workup included pulmonary function tests with
diffusion capacity (DLCO) and blood gas analysis, chest
x-rays, computed tomography (CT) of the chest and upper
abdomen, bronchoscopy, and, since 2000, positron emission
tomography (PET) scan (recently integrated PET-CT scan).
Mediastinoscopy was performed in the presence of enlarged
(15 mm) lymph nodes at CT scan or, more recently,
positive at PET scan. Operative procedure included in all
cases pulmonary resection (wedge, segmentectomy, lobec-
tomy, bilobectomy, or pneumonectomy) and systemic lymph-
adenectomy. All patients were staged according to the 7th
edition of the TNM staging system.6
Follow-up information on all patients was obtained
through clinic follow-up notes, direct patient or family con-
tact, or contact with the patient’s primary care physician.
For analysis, the following histopathologic variables
were considered in the two population groups, MVI and
MVI: histology, histologic grading of differentiation (well,
moderately, and poorly differentiated, respectively, G1, G2,
and G3), tumor size, microscopic perineural invasion, and the
presence of tumor-infiltrating lymphocytes (TIL).
Histopathological Evaluation
The surgical specimens were immediately fixed in 10%
formalin and underwent routine histopathological workup
with paraffin embedding. A sampling of the tumor mass at
every centimeter was undertaken, and a 1.5  2  0.5 cm
(0.5-cm width) slice was obtained. For a mean tumor diam-
eter of 36 mm (range, 0.9–7 cm), a mean of 4.5 slices (range,
2–7) were undertaken. Routine hematoxylin–eosin stain was
used for all slices.
MVI was defined as the presence of neoplastic struc-
tures inside the lumen of a vessel, either blood or lymphatic
vessel. In most cases, it was characterized by neoplastic cells
embedded in organized vascular thrombosis. If there was any
doubt whether the neoplastic cells could represent artifacts,
the specimen underwent three to four consecutive serial
sections, documenting the presence or absence of infiltration
of the vascular wall; furthermore, an immunohistochemical
staining with antibody anti-CD34 (Monoclonal Mouse Anti-
Human CD34 Class II, clone QBEnd 10, DAKO, Milan,
Italy) was performed to evaluate blood vessels.
The presence or absence of TIL was defined as CD8
intraepithelial lymphocytes morphologically identified within
the cancer cell nests, and patients were collected in two
different groups, TIL-positive and TIL-negative, as described
in our previous study.7 The presence of perineural invasion
was defined to be the tumoral involvement of epineurium in
the peritumoral tissue.
Statistical Analysis
Comparison between proportion differences was under-
taken using 2 test (Fisher’s exact test when appropriate). To
investigate the relationship between some possible causal
(independent) variables and the presence/absence of MVI,
considered as a binary variable, a logistic regression model
was used,8 with the assumption that the events were indepen-
dent and the relationship plausibly log-linear. The probability
value was calculated on the Wald statistic, and 95% confi-
dence intervals (CIs) were also provided. When the outcome
variable was ordinal (such as in case of the T-size descrip-
tors), ordinal regression was used, and the cumulative logit
model was employed.9
Cumulative survival rates were calculated by the
Kaplan-Meier method, using the date of surgery as the start-
ing point and the date of death or the latest follow-up date as
the end point. The survival differences were determined by
log-rank analysis. Calculation of the relative hazards and the
relative 95% confidence intervals using the Cox proportional
hazard model was used. A p value less than 0.05 was
considered statistically significant. A formal test of interac-
tion was performed before proceeding with the subgroup
analysis for the variables of interest. All statistical analysis
was undertaken using software packages (STATISTICA, re-
lease 7.1, 2005, Statsoft, Italy).
The study was approved by our institutional review
board, and individual patient consent was waived because of
the retrospective nature of the study.
RESULTS
Table 1 illustrates the patients characteristics. The pa-
tients were stratified according to the newest TNM edition
(7th) into T1a (2 cm, N  173), T1b (2 but not 3 cm,
N  238), T2a (3 but not 5 cm, N  263), and T2b (5
but not7 cm, N 72). The corresponding stages were stage
IA (T1a  T1b), stage IB (T2a), and stage IIA (T2b).
MVI Prevalence
Overall, MVI was observed in 257 patients (34%). In
77 cases (77 of 257 cases, 30%), immunohistochemical
staining with CD34 was necessary for the final diagnosis of
MVI. MVI prevalence was significantly higher in adenocar-
cinoma (159 patients, 44%) than in squamous cell carcinoma
(81 patients, 27%) (p  0.002) and large cell carcinoma (7
patients, 32%).
Ruffini et al. Journal of Thoracic Oncology • Volume 6, Number 2, February 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer320
Correlations of MVI with Clinicopathologic
Variables
Using logistic regression model, the presence of MVI
was tested against different clinicopathologic variables, in-
cluding age, gender, grading, TIL, histology, and tumor size.
Among all the variables, MVI was significantly associated
with the presence of TIL (odds ratio [OR] 1.54, 95% CI
1.09–2.24, p 0.02), an increased tumor size (OR 1.13, 95%
CI 1.01–1.24, p  0.05), and adenocarcinoma histotype (OR
1.20, 95% CI 1.08–2.48, p  0.03).
The Association Between T-Size Categories
and MVI
A dedicated analysis was undertaken to look at the
association between the T-size categories (T1a through T2b)
according to the 2009 7th edition of the TNM staging system
and the presence of MVI. Prevalence of MVI increased with
the T predictor from T1a (49 patients, 28%) to T2b (29
patients, 40%) (Table 2). When using an ordinal regression
model with T-size categories as dependent variable and the
following independent variables (histology, MVI, perineural
invasion, TIL, and grading), histology (adenocarcinoma type,
p  0.03), MVI (p  0.04), and grading (p  0.00003) all
significantly correlated with increasing T size (Table 3).
Univariate and Multivariate Survival Analysis
Follow-up with vital status was available for all pa-
tients. Mean follow-up time was 53 months.
In univariate survival analysis, the presence of MVI on
the overall patient population was associated with a signifi-
cant decreased survival (65% versus 55% at 5 years for
MVI and MVI populations, respectively; p  0.001)
(Figure 1).
We further analyzed the study population by histology
considering the two histotypes, adenocarcinoma and squa-
mous cell carcinoma.
FIGURE 1. Overall survival of the study population accord-
ing to the presence/absence of microscopic vascular inva-
sion. MST, mean survival time.
 
Patients at risk (Yrs)  0 2 4 6 8 10 12 14 
MVI -    489 350 245 160 106 53 22 1 
MVI +    257 162 80 40 13 3 1 - 
TABLE 1. Patients Characteristics of the Study Population
N %
Age, mean (range) 65 (37–82)
M/F 612/134 82/18
Histology
Adenocarcinoma 359 48
Squamous cell 295 39
BAC 55 7
Large cell 22 3
Others 15 2
Resection
Wedge/segment 80/21 13
Lob/bilobectomy 557/12 76
Pneumonectomy 76 10
Gradinga
G1 109 15
G2 342 49
G3 247 35
T size, cm, mean (range) 3.6 (0.9–7)
T categoriesb
T1a (2 cm) 173
T1b (2–3 cm) 238
T2a (3–5 cm) 263
T2b (5–7 cm) 72
aAvailable for 698 patients.
bAccording to the 2009 TNM staging system.
BAC, bronchioloalveolar carcinoma; TNM, tumor, node, metastasis.
TABLE 2. MVI Prevalence According to Different T-Size
Categories of the 2009 7th Edition of the TNM Staging
System for Lung Cancer
T Status MVI, n (%) MVI, n (%)
T1a 49 (28) 124 (72)
T1b 76 (32) 162 (68)
T2a 109 (41) 154 (59)
T2b 29 (40) 43 (61)
MVI, microscopic vascular invasion; TNM, tumor, node, metastasis.
TABLE 3. Ordinal Regression Analysis
Wald Statistic p
Perineural invasion 0.1903 0.662
MVI 4.1181 0.004
TIL 0.0073 0.931
Grading 17.113 0.00003
Histology (adenocarcinoma type) 4.4520 0.003
Dependent variable: T-size determinant T1a through T2b according to the 2009 7th
Edition TNM staging system for lung cancer.
MVI, microscopic vascular invasion; TIL, tumor-infiltrating lymphocytes.
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In patients with squamous cell carcinoma, the presence
of MVI was not associated with a significant 5-year survival
difference versus patients without MVI (59% versus 49% in
MVI and MVI, respectively; p  0.25). Conversely, in
patients with adenocarcinoma, the presence of MVI was
significantly associated with a poorer 5-year survival (71%
versus 60% in MVI and MVI, respectively; p  0.002)
(Figure 2). In the subgroup analysis, the interaction between
MVI and histology was assessed using a test of interaction,
by including in the multivariate Cox method an additional
variable of interaction defined as the product of the two
variables, MVI and histology (adenocarcinoma versus squa-
mous cell carcinoma).
The test of interaction provided a marginal level of
significance (p  0.06). Therefore, we may suggest that the
survival differences by histology in the MVI and MVI
groups are important, although we cannot draw any conclu-
sion from a statistical point of view that the relationship
between MVI and survival is different in adenocarcinoma
versus squamous cell types. A possible explanation may be
that the study had no statistical power to detect survival
differences at the conventional (p  0.05) level of signif-
icance because of the sample size or limitations in the
study design.
We then performed a multivariate survival analysis
using different covariates, including age, sex, grading, tumor
size, MVI, perineural invasion, TIL, histology, and stage. The
presence of MVI was an independent prognostic factor either
overall (HR 1.61, 95% CI 1.30–2.15, p  0.003) or in
adenocarcinoma histotype (HR 2.02, 95% CI 1.36–3-02, p 
0.0005) but not in squamous cell type (HR 1.21, 95% CI
0.82–1.80, p  0.59).
A dedicated survival analysis was undertaken, ex-
ploring the prognostic significance of MVI in four differ-
ent T-size categories (T1a through T2b) according to the
2009 7th edition of the TNM staging system along with the
combination of the effects of MVI and T-size determinant.
In each T-size category, and when grouping T-size cate-
gories into T1a  T1b and T2a  T2b, the presence of
MVI had a negative prognostic impact overall (Figure 3,
Table 4), and this was more evident in adenocarcinoma
(Figure 4). Survival in MVI patients was similar among
the four T size groups, T1a, T1b, T2a, and T2b (p  0.90)
either overall or in adenocarcinoma (p  0.72). Interest-
ingly, T1a and T1b MVI patients had a survival similar
to T2a and T2b MVI patients (5-year survival: 61%
versus 62%, respectively, p  0.46; Table 4). Therefore,
our results seem to suggest that MVI is a more powerful
prognostic indicator than size in early-stage pT1-T2N0
NSCLC patients.
DISCUSSION
This study was aimed at investigating the role of MVI
in the clinical presentation and outcome of early-stage
NSCLC along with the analysis of the effect of the combi-
nation of MVI and tumor size for the T-size categories T1a
through T2b using the 2009 7th edition of the TNM classi-
fication.
The results of the study indicate that (1) MVI is
frequent in resected patients with NSCLC; (2) MVI correlates
with the tumor size, the presence of TIL, and the adenocar-
FIGURE 2. Survival of the study population according to
the presence/absence of microscopic vascular invasion and
adenocarcinoma histotype. MST, mean survival time; N.R.,
not reached.
 
Patients at risk (Yrs)  0 2 4 6 8 10 12 14 
MVI -    200 136 97 56 42 18 7 1 
MVI +    159 104 51 23 11 2 1 - 
FIGURE 3. Survival curves stratified by T-size categories
T1a-T2b according to the 2009 7th edition of the tumor,
node, metastasis (TNM) staging system for lung cancer and
the presence/absence of microscopic vascular invasion in the
study population overall. MST, mean survival time.
 
Patients at risk (Yrs)  0 2 4 6 8 10 12 14 
T1a+T1b MVI -  275 186 138 98 56 26 12 1 
T2a+T2b MVI -  190 164 102 64 47 36 11 1 
T1a+T1b MVI +  118 68 28 14 6 1 - - 
T2a+T2b MVI +  129 89 45 20 13 1 1 - 
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cinoma type; (3) MVI is an independent negative prognostic
factor; (4) the new 2009 7th edition of the TNM staging
system underestimates the presence of MVI, which, at least in
T1a through T2b size categories, has a greater prognostic
impact than size.
BVI is one of the steps leading to metastatic diffusion.
It has been demonstrated that during the early stages of tumor
growth, angiogenesis is required to foster tumor progression.
Tumor cells from the primary neoplasm may penetrate these
new vessels and escape from the primary site to distant
organs.4 The relationship between tumor vessels, intravascu-
lar tumor cell invasion, and metastases has been studied in
animal models. The first studies about the prognostic role of
MVI in lung cancer date back to the late 1950s. Since then,
numerous studied have investigated the importance of MVI in
the progression of lung cancer.
Surprisingly, no TNM staging system of lung cancer so
far has incorporated MVI in the determinants of prognosis,
and even the 2009 7th edition of the TNM staging includes
lymphatic and venous invasion as “optional descriptors,”6
which deserve further investigation. Studies investigating the
importance of MVI in relation to stage and T determinant
have been published in the past decades. Back in the mid-
1990s, Kessler et al.4 suggested that vascular invasion should
be considered superior to T descriptor as a prognostic factor.
Macchiarini et al.10 observed that in tumor with a high degree
of angiogenesis, MVI was significantly more frequent. As a
consequence, it has been speculated that the presence of MVI
is an indicator for the presence of occult metastases and
therefore these patients might be considered candidates to a
postoperative chemotherapy. More recently, Tsuchiya et al.3
observed on a large series of 322 stage IA patients, staged
according to the 6th TNM edition, that the overall 5-year
survival rate of patients with MVI stage IA was similar to
that of MVI stage IB patients. Similarly, MVI stage IB
patients had similar survival rates as MVI stage IIA pa-
tients. Therefore, they recommended to upgrade MVI stage
IA and IB patients to stage IB and IIA, respectively. The only
report published so far about MVI, using the newest TNM
staging system, from a Japanese series11 clearly confirms that
in pathologic stage IA NSCLC, disease-free survival in MVI
 T1a (2 cm) and T1b (2–3 cm) was significantly poor. In
our series, T1a through T2b size categories, patients with
MVI had nonsignificantly different survival rates, although
significantly lower than the corresponding MVI categories,
thus demonstrating that MVI was a far more powerful prog-
nostic indicator than size in T1-T2 size categories NSCLC.
Therefore, there are numerous reports, including ours, indi-
cating that at least in early-stage NSCLC, MVI is a far more
important determinant than size and should therefore be taken
into account for staging.
As a consequence, most authors recommend to use
adjuvant chemotherapy in MVI patients irrespective of the
stage. Several recent trials have shown that cisplatin-based
chemotherapy after resection of NSCLC may be beneficial.
The Lung Adjuvant Cisplatin Evaluation meta-analysis12
found an overall hazard ratio (HR) of 0.89, thus demon-
strating a proven benefit of adjuvant chemotherapy. The
same meta-analysis, however, failed to demonstrate a sur-
vival advantage (HR 1.40) in pathologic stage IA. There-
fore, the current practice is not to administer postoperative
chemotherapy in stage IA NSCLC patients. The results
FIGURE 4. Survival curves stratified by T-size categories
T1a-T2b according to the 2009 7th edition of the tumor,
node, metastasis (TNM) staging system for lung cancer and
the presence/absence of microscopic vascular invasion in the
study population, adenocarcinoma histotype. MST, mean
survival time; N.R., not reached.
 
Patients at risk (Yrs)  0 2 4 6 8 10 12 14 
T1a+T1b MVI -  130 98 67 30 24 7 2 1 
T2a+T2b MVI -  63 44 30 21 16 9 3 1 
T1a+T1b MVI +  82 49 22 10 4 2 - -  
T2a+T2b MVI +  75 55 29 10 6 1 1 -   
TABLE 4. Median Survival Time and 5-yr Survival Rates for
the Four T-Size Categories T1a through T2b in the Two
Population Groups MVI and MVI
T-Size Category Median Survival
5-yr Survival
(%)
T1a (2 cm)
MVI NR 75
MVI 91 61
T1b (2 but not 3 cm)
MVI 116 66
MVI 68 61
T2a (3 but not 5 cm)
MVI 103 64
MVI 69 52
T2b (5 but not 7 cm)
MVI 86 61
MVI 55 50
T1a  T1b
MVI 135 70
MVI 77 61
T2a  T2b
MVI 100 62
MVI 64 51
MVI, microscopic vascular invasion; NR, not reached.
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obtained so far about the role of MVI in early-stage lung
cancer, including stage IA, may change the scenario. The
finding of MVI has been discussed extensively in the
literature as an indication for adjuvant chemother-
apy,9,10,13–15 although this continues not to be recognized
as a standard treatment according to European guidelines.
A recent Japanese study3 using oral uracil-tegafur chemo-
therapy demonstrated an increased 5-year survival in stage
IA MVI patients by more than 25%. Other authors13
found that MVI significantly correlated with vascular en-
dothelial growth factor (VEGF) expression, and oral ura-
cil-tegafur or other VEGF inhibitors may be effective in
these high-risk patients.
The implications of a correct staging for patients
with clinicopathologic prognosticators including MVI is of
utmost importance in early-stage NSCLC, where the
chance of cure is high and the potential benefits of multi-
modality treatment have been demonstrated. The issue is
of primary importance because the frequency of detecting
stage IA NSCLC has been increasing over the recent years
due to refinement and improvement in diagnostic tech-
niques and mass screening programs. Watanabe et al.16
reported that the proportion of patients with stage IA
NSCLC has increased from 19% in 1991 to 26% in 1998,
and it is steadily increasing in the more recent years. The
more precise the identification of prognostic subgroups in
these early stages, the more “targeted” would be optimal
treatment to these patients. Therefore, the literature and
our own work support the hypothesis that MVI should be
incorporated in the TNM staging system, as it is currently
being adopted for liver, testicular, and breast carcinoma.17
Table 5 summarizes the results of the major series
published so far about the role of MVI in NSCLC. Al-
though the study populations were different, comprising
different stages and different number of patients, the
majority of the studies indicate that MVI is a significant
prognostic indicator. Some authors differentiate between
blood vessel and LVI,18,19 whereas others tend to consider
the MVI irrespective of the type of vessel (blood or
lymphatic). Some authors reported that only LVI but not
BVI is significantly related to a decreased survival,2,20,21
whereas other reports stated the opposite12 and indicated
that cells from early-stage NSCLC metastasize preferen-
tially via the blood vessels, and thus MVI is a more
reliable prognosticator.9,10,14,22–24 Finally, some reports in-
dicate that both blood and lymphatic invasion were signif-
icantly associated with a poor prognosis.3,25 Studies that
only focused on either vascular or lymphatic permeation
failed to reach an agreement about which of the two
components has an impact on survival. A further confusion
in the interpretation of the results arises because of the
debate of the significance of large vessels (arteriolar or
venous) or small vessels (primarily lymphatic) invasion.
Also, it is often impossible to identify the vessel type
(arterial or venous) in the tumor. We, as other authors,3
decided to consider MVI as a combination of blood and
LVI to reduce the pathologic confusion and to limit the
number of subgroups. Another source of confusion stems
from the lack of standardized criteria among the patholo-
gists for the definition of MVI, and each pathologist has
his or her own subjective diagnostic criteria, which may
explain the difference in the results among the reported
series; theoretically, the frequency of MVI is proportional
to the number of slides examined, and for this reason, the
best method to identify MVI in a tumor is to examine all
serial sections prepared from the tumor material. Some
authors3 recommend to examine at least two slides per
tumor and two blocks per centimeter (5-mm slices) of the
tumor. The same authors suggest to use specific markers
for normal and tumor-associated lymphatics, such as Ab
antiD2-40. Because of the importance of MVI in the
prognosis of patients with NSCLC, an agreement among
the pathologists regarding tissue sampling, examination
protocols, and the use of specific immunohistochemical
markers is strongly needed.
Prevalence of MVI is extremely variable in the reported
series, depending on the care of the pathologist to look for it
and the different stages examined, ranging from as low as 9%
TABLE 5. Results About MVI in the Literature
Author (Year) N Stages MVI Prevalence (%) Prognostic Significance Correlations
Rigau (2002) 86 All stages 29 No NS
Mineo (2004) 51 IB–IIA 25 Yes Grading, tumor size
Khan (2004) 98 T1–T2N1 10 Yes NS
Kessler (1996) 593 All stages NS Yes NS
Tsuchiya (2007) 995 I–II 50 Yes NS
Tsuchiya (2007) 322 IA 26 Yes CEA, tumor size
Gabor (2004) 72 T1–T3N0 32 Yes No
Poncelet (2008) 346 I–II 14 No T, grading
Bodendorf (2008) 112 All stages 45 Yes Tumor size, ADK
Brechot (1996) 96 All stages 52 No Tumor size
Shoji (2010) 217 IA 9 Yes No
This Study 746 I–II 34 Yes Tumor size, ADK, TIL
Mean MVI prevalence 29
MVI, microscopic vascular invasion; NS, not stated; ADK, adenocarcinoma; TIL, tumor-infiltrating lymphocytes.
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to as high as 60% (Table 4). Our prevalence of 31% is in
accordance with that of the literature. Few studies have
looked for possible correlations between MVI and different
clinicopathologic variables. Poncelet et al.,26 in a patient
population of more than 300 stage I–II NSCLC patients,
found a correlation between MVI and T factor and grading.
Tsuchiya et al.3 in stage I patients correlated MVI with serum
CEA levels and tumor size, and Bodendorf et al.5 in NSCLC
from all stages found a correlation between MVI and tumor
size and adenocarcinoma type. In this series, using a logistic
regression model, we found that MVI significantly correlates
with tumor size, adenocarcinoma type, and the presence of
TIL. The correlation with tumor size has been confirmed
when we performed an ordinal regression model using the
T-size descriptors of the newest edition of TNM (T1a through
T2b) as the dependent variable and the presence/absence of
MVI as independent variable, and the correlation was highly
significant. Therefore, we may have hypothesized that as the
tumor increases, new vessels are formed, and the permeation
by tumor cells through the neovessels is increased. In our
previous study investigating the role of TIL in lung neo-
plasms,7 a significant correlation emerged between TIL and
MVI, grading, and tumor dimension. This suggests that
immune cell reactions are more pronounced, as the tumor
dedifferentiation and biologic malignant behavior (including
vascular permeation by tumor cells) progress. Similar results
were obtained in NSCLC by other authors27,28 and in other
human solid organ tumors.29,30 Therefore, it seems hypothe-
sized that a complex inter-relationship takes place in the
tumoral and peritumoral microenvironment where neoangio-
genesis, immunogenicity, and intrinsic characteristics of the
tumoral cell lines (histotype and the degree of differentiation)
all have a role in determining tumor progression. We are just
starting to understand these complex interactions, which may
profoundly influence our treatment strategies with targeted
therapies.
This study has some limitations including the retro-
spective nature of the study design and the long time
interval of the patient series, both of which should surely
be taken into account for the interpretation of the results.
However, we would point out that, despite the relatively
long time period (15 years), the surgical team has remained
the same over the whole period, and the surgical tech-
niques have been maintained basically constant, and this
may partly offset the aforementioned limitations. An ad-
ditional point to be considered is that the outcome measure
adopted in this study was the all-cause mortality. Although
it may be argued that this might have excluded noncancer-
related deaths, it is worth noticing that in our country, like
in other countries,31 patients with a diagnosis of lung
cancer will have this condition listed on the death certifi-
cate irrespective of the actual cause of death. This makes
the identification of noncancer-related deaths very diffi-
cult. Also, as pointed out elsewhere,32 such an attempt may
itself introduce a potential bias by excluding the contribu-
tion of an undiagnosed recurrent malignancy in an appar-
ently noncancer-related death.
We conclude that in resected patients with pT1-T2N0
NSCLC, the finding of MVI in the surgical specimen is
frequent, occurring in up to one-third of the cases. MVI
correlates with important clinicopathologic variables, in-
cluding tumor size, adenocarcinoma type, and TIL. MVI
represents a poor prognostic factor, which in our experi-
ence was a more important prognostic determinant than
size in T1a through T2b size categories according to the
2009 TNM staging system. Patients with MVI are there-
fore to be considered a high-risk group among patients
with early-stage NSCLC. We recommend that pathologists
dealing with NSCLC need to perform a meticulous search
for MVI in every patient operated on for NSCLC, and the
presence of MVI in the surgical specimen should be
emphasized and reported to the surgeon and the medical
oncologist. As a final consequence, our study suggests that
upstaging of patients with MVI is strongly recommended
as well as consideration for adjuvant chemotherapy in this
high-risk group of patients.
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